Specialty products continued to dominate new drug and biologic approvals in the US in a year in which the evolving regulatory environment also featured heavily.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Hughes, B. 2008 FDA drug approvals. Nat Rev Drug Discov 8, 93–96 (2009). https://doi.org/10.1038/nrd2813
Issue Date:
DOI: https://doi.org/10.1038/nrd2813
This article is cited by
-
Clustering Effect on Bioactivity of Calixarene-Based Tetramers
Pharmaceutical Chemistry Journal (2020)
-
An on-chip intestine-liver model for multiple drugs absorption and metabolism behavior simulation
Science China Chemistry (2018)
-
Microfluidic Gut-liver chip for reproducing the first pass metabolism
Biomedical Microdevices (2017)
-
Dose effects of lacosamide as add-on therapy for partial-onset seizure in adult
Neurological Sciences (2016)
